The screening project SAFER enters the final phase of screening

Stockholm 16 November 2023

People from over a hundred health centers in England are being screened for atrial fibrillation at a high rate with Zenicor One as the SAFER trial enters its final phase. About 70% of the participants have now been screened and all inclusion of participants are expected to be completed by late spring 2024. The first preliminary analysis of the results is planned to be done in July 2025.